The second most advanced product candidate in our generics pipeline is venlafaxine HCI, a generic version of the marketed drug Effexor XR®. This product is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) and is available for partnering.
Effexor XR® is an extended-release capsule for oral administration that contains venlafaxine hydrochloride. It is indicated for the treatment of symptoms of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. According to Source Healthcare Analytics, sales of venlafaxine hydrochloride extended-release capsules in the U.S. were approximately US$815 million for the 12 months ended December 2012.